Hans Schikan elected as new Board member in Hansa Medical AB (publ)

The annual general meeting of Hansa Medical AB (publ), held on 2 June 2015,
elected Hans Schikan as new Board member.
Hans GCP Schikan, born 1958. Pharmacist, Utrecht University.
Other appointments: Supervisory Board member of Prosensa, The Netherlands. Board
member of Swedish Orphan Biovitrum AB (publ) and Top Team Dutch Top Sector Life
Sciences & Health. Member of the Biotechnology Industry Organization’s Emerging
Companies Section Governing Board. Member of the Advisory Board of BioScience
Park Leiden.
Previous appointments: CEO of Prosensa. Chairman of Dutch Association of the
Innovative Pharmaceutical Industry, Nefarma. Various senior management positions
within previous Organon and Genzyme. Board member of Top Institute Pharma.

The information in this press release is disclosed pursuant to the Securities
Markets Act or the Financial Instruments Trading Act. The information was
released for public disclosure on June 3, 2015, at 08.45 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO and CFO
Mobile: 46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused
on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading
enzyme in clinical development, with potential use in transplantation and rare
autoimmune diseases. Other projects include HBP (a market introduced diagnostic
marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in
pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's
share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB
as Certified Adviser.